Showing results (291-300 of 458) with videos related to

Sort By:
Pageof 46
Pediatric Blood & Cancer|September 30, 2014
Initial testing (stage 1) of the PARP inhibitor BMN 673 by the pediatric preclinical testing program: PALB2 mutation predicts exceptional in vivo response to BMN 673Malcolm A Smith, Oliver A Hampton, C Patrick Reynolds, et al.
Pediatric Blood & Cancer|July 2, 2013
Phase I trial of fenretinide delivered orally in a novel organized lipid complex in patients with relapsed/refractory neuroblastoma: a report from the New Approaches to Neuroblastoma Therapy (NANT) consortiumBarry J Maurer, Min H Kang, Judith G Villablanca, et al.
Neoplasia (New York, N.Y.)|April 28, 2020
LIN28B promotes neuroblastoma metastasis and regulates PDZ binding kinaseDongdong Chen, Julie Cox, Jayabhargav Annam, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 18, 2006
A phase 1 study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 7 days every 21 days in pediatric patients with solid tumorsElizabeth Fox, John M Maris, Brigitte C Widemann, et al.
Cancer Cell|October 21, 2015
A LIN28B-RAN-AURKA Signaling Network Promotes Neuroblastoma TumorigenesisRobert W Schnepp, Priya Khurana, Edward F Attiyeh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 21, 2019
Phase I Clinical Trial of the Wee1 Inhibitor Adavosertib (AZD1775) with Irinotecan in Children with Relapsed Solid Tumors: A COG Phase I Consortium Report (ADVL1312)Kristina A Cole, Sharmistha Pal, Rachel A Kudgus, et al.
Pediatric Blood & Cancer|April 21, 2020
Limited antitumor activity of combined BET and MEK inhibition in neuroblastomaJason R Healy, Lori S Hart, Alexander L Shazad, et al.
Pediatric Blood & Cancer|September 17, 2011
Initial testing of JNJ-26854165 (Serdemetan) by the pediatric preclinical testing programMalcolm A Smith, Richard Gorlick, E Anders Kolb, et al.
Molecular Oncology|February 1, 2021
Epigenetic regulator BMI1 promotes alveolar rhabdomyosarcoma proliferation and constitutes a novel therapeutic targetCara E Shields, Sindhu Potlapalli, Selma M Cuya-Smith, et al.
Pediatric Blood & Cancer|September 24, 2015
Pharmacodynamic and genomic markers associated with response to the XPO1/CRM1 inhibitor selinexor (KPT-330): A report from the pediatric preclinical testing programEdward F Attiyeh, John M Maris, Richard Lock, et al.
Pageof 46